Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports

AbstractRationale:In the setting of metastatic or locally advanced adrenocortical carcinoma, a limited number of therapies are available and their efficacy is generally below modest. The backbone of treatment remains surgery, even for metastatic disease, whenever it is possible, and mitotane. Chemot